Privacy Policy

Last Updated: 5/2/2017

Mist Pharmaceuticals, LLC (“Mist Pharmaceuticals,” “we,” “us,” or “our”) has created this privacy policy (this “Privacy Policy”) because we know that you care about how information you provide to us is used and shared. This Privacy Policy relates to our information collection and use of your information when you visit any website operated by Mist Pharmaceuticals (collectively, the “Sites”) and/or purchase the products made available through these Sites (“Products”).

By visiting our Site(s) and/or purchasing our Products, you are agreeing to the terms of this Privacy Policy and the accompanying Terms of Use. Capitalized terms not defined in this Privacy Policy shall have the meaning set forth in our Terms of Use.

The Information We Collect and/or Receive

In the course of operating the Sites, we will collect (and/or receive) the following types of information. You authorize us to collect and/or receive such information.

  • Personal Information

    If you contact us via the Contact Us page or by any other means through the Site(s), you will be asked to provide certain information which may include your name, e-mail address, phone number, and company name. If you would like to participate in our patient savings program for the Product(s), you will be asked to provide certain information about yourself which may include your name, address, date of birth, zip code, social security number, phone number, gender, physician’s name, physician’s phone number, physician’s zip code, and insurance/payer information.

    All information we collect and/or receive under this section is collectively called “Personal Information.”

  • Other Information

    In addition to the Personal Information we may collect additional information (the “Other Information”). Such Other Information may include:

    1. From Your Activity. In an ongoing effort to improve the Sites and to determine which Mist Pharmaceuticals services are popular, we automatically collect certain information when you visit the Sites. Such information includes, without limitation, your IP address, browser type and language, domain names, referring and exit pages and URLs, date and time, amount of time spent on particular pages, what sections of the Sites visitors visit, and similar information concerning your use of the Sites.
    2. From Cookies. The Sites use “cookies” to help us personalize your online experience. A cookie is a text file that is placed on your hard disk by a web page server. Cookies cannot be used to run programs or deliver viruses to your computer. Cookies are uniquely assigned to you, and can only be read by a web server in the domain that issued the cookie to you. One of the primary purposes of cookies is to provide a convenience feature to save you time. The purpose of a cookie is to tell the web server that you have returned to a specific page. For example, if you personalize Mist Pharmaceuticals pages, or register with Sites or services, a cookie helps Mist Pharmaceuticals to recall your specific information on subsequent visits. When you return to the same Site, the information you previously provided can be retrieved, so you can easily use the Mist Pharmaceuticals features that you customized. You have the ability to accept or decline cookies. Most web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies if you prefer. If you choose to decline cookies, you may not be able to fully experience the interactive features of the Sites.
    3. Third Party Analytics. We use third-party analytics services (such as Google Analytics) to evaluate your use of the Site(s), compile reports on activity, analyze performance metrics, and collect and evaluate other information relating to the Site(s) and Internet usage. These third parties use cookies and other technologies to help analyze and provide us the data. By accessing and using the Site(s), you consent to the processing of data about you by these analytics providers in the manner and for the purposes set out in this Privacy Policy. The third-party analytics service providers we currently work with are those listed below. These third parties may change from time to time, but in each case we will provide you with the links to view such parties’ privacy policies and find out more about what data they hold about you, what they do with it, and how to opt-out from certain data collection.

      [https://www.google.com/intl/en/policies/privacy/]

Please be advised that if you opt out of any service, you may not be able to use the full functionality of the Site(s).

Information Collected by or Through Third-Party Advertising Companies

We may share Other Information about you with third parties for ad distribution and ad optimization (defined as the tailoring, targeting (i.e., behavioral, contextual, and retargeting), analyzing, managing, reporting, and optimizing of ads). These third parties may use cookies, pixel tags (also called web beacons or clear gifs), and/or other technologies to collect such Other Information for such purposes. Pixel tags enable us, and these third-parties, to recognize a browser’s cookie when a browser visits the site on which the pixel tag is located in order to learn which advertisement brings a user to a given site. You may opt-out of the tailoring of advertising based on information we collect. To learn more about the use of this information, or to choose not to have this information used by our providers or third party advertising partners by opting out, please visit the Network Advertising Initiative by clicking http://www.networkadvertising.org/managing/opt_out.asp.

How We Use and Share the Information

You authorize us to use your Personal Information, and Other Information (collectively, the “Information”) to provide and improve our Sites; to maintain quality of the service; to solicit your feedback; to inform you about our company, products and services; to contact you via surveys to conduct research about your opinion of current services or of potential new services that may be offered; and to contact you on behalf of external business partners about a particular offering that may be of interest to you.

We do not collect or ask you to provide any sensitive personal information, such as race, religion or political affiliations. But if you provide any such sensitive personal information to us, Mist Pharmaceuticals will not use or disclose any such sensitive personal information, without your explicit consent.

You also authorize us to use and/or share your Information as described below.

  • Agents, Providers and Related Third Parties. We may engage other companies and individuals to perform certain business-related functions on our behalf. Examples may include providing technical assistance, order fulfillment, customer service, and marketing assistance. These other companies will have access to the Information only as necessary to perform their functions and to the extent permitted by law. We may also share your Information with any of our parent companies, subsidiaries, or other companies under common control with us.
  • Aggregated Information. In an ongoing effort to better understand our users and the Sites, we might analyze your Information in aggregate form in order to operate, maintain, manage, and improve the Sites. This aggregate information does not identify you personally. We may share this aggregate data with our affiliates, agents, and business partners. We may also disclose aggregated user statistics in order to describe the Sites to current and prospective business partners and to other third parties for other lawful purposes.
  • Business Transfers. As we develop our businesses, we might sell or buy businesses or assets. In the event of a corporate sale, merger, reorganization, sale of assets, dissolution, or similar event, your Information may be part of the transferred assets.
  • Legal Requirements. To the extent permitted by law, we may also disclose your Information: (i) when required by law, court order, or other government or law enforcement authority or regulatory agency; or (ii) whenever we believe that disclosing such information is necessary or advisable, for example, to protect the rights, property, or safety of Mist Pharmaceuticals or others.

Accessing and Modifying Information and Communication Preferences

If you have provided us any Personal Information, you may access, remove, review, and/or make changes to the same by contacting us at info@mistpharma.com. In addition, you may manage your receipt of marketing and non-transactional communications by clicking on the “unsubscribe” link located on the bottom of any Mist Pharmaceuticals marketing e-mail. We will use commercially reasonable efforts to process such requests in a timely manner. You should be aware, however, that it is not always possible to completely remove or modify information in our subscription databases.

Security of your Personal Information

Mist Pharmaceuticals takes commercially reasonable steps to protect your Personal Information from unauthorized access, use, disclosure, loss, misuse, alteration, or destruction. Please understand, however, that no security system is impenetrable. We cannot guarantee the security of our databases or the databases of the third parties with which we may share such information, nor can we guarantee that the information you supply will not be intercepted while being transmitted over the Internet. In particular, e-mail sent to us may not be secure, and you should therefore take special care in deciding what information you send to us via e-mail.

External Websites

The Sites may contain links to external websites. Mist Pharmaceuticals encourages you to review the privacy statements of such external websites you choose to link to from Mist Pharmaceuticals so that you can understand how those external websites collect, use and share your information. Mist Pharmaceuticals is not responsible for the privacy statements or other content on such external websites. You should check the application third-party privacy policy and terms of use when visiting any such external website.

Children

We do not knowingly collect Personal Information from children under the age of 13 through the Sites. If you are under 13, please do not give us any Personal Information. We encourage parents and legal guardians to monitor their children’s Internet usage and to help enforce our Privacy Policy by instructing their children never to provide Personal Information through the Sites without their permission. If you have reason to believe that a child under the age of 13 has provided Personal Information to us, please contact us, and we will endeavor to delete that information from our databases.

Important Notice to Non-U.S. Residents

The Sites and the servers are operated in the United States. If you are located outside of the United States, please be aware that any information you provide to us maybe transferred to, processed, maintained, and used on computers, servers, and systems located outside of your state, province, country, or other governmental jurisdiction where the privacy laws may not be as protective as those in your jurisdiction. If you are located outside the United States and choose to use the Sites, you hereby irrevocably and unconditionally consent to such transfer, processing, and use in the United States and elsewhere.

California Residents

Under California Civil Code Section 1798.83, California residents who have an established business relationship with Mist Pharmaceuticals may choose to opt out of our sharing their personal information with third parties for direct marketing purposes. If you are a California resident and (1) you wish to opt out; or (2) you wish to request certain information regarding our disclosure of your personal information to third parties for the direct marketing purposes, please send an e-mail to info@mistpharma.com with “Privacy Policy” in the subject line or write to us at:

Mist Pharmaceuticals, LLC
11 Commerce Dr, 1st Floor
Cranford, NJ 07016

In addition, Mist Pharmaceuticals does not monitor, recognize, or honor any opt-out or do not track mechanisms, including general web browser “Do Not Track” settings and/or signals.

Changes to This Privacy Policy

This Privacy Policy is effective as of the date stated at the top of this Privacy Policy. We may change this Privacy Policy from time to time with or without notice to you. Any such changes will be posted on the Sites. By accessing the Site(s) and/or purchasing the Products after we make any such changes to this Privacy Policy, you are deemed to have accepted such changes. Please be aware that, to the extent permitted by applicable law, our use of your information is governed by the Privacy Policy in effect at the time we collect the Information. Please refer back to this Privacy Policy on a regular basis.

Contact Information

Mist Pharmaceuticals welcomes your comments regarding this Privacy Policy. If you believe that Mist Pharmaceuticals has not adhered to this Privacy Policy, please contact Mist Pharmaceuticals at info@mistpharma.com. We will use commercially reasonable efforts to promptly determine and remedy the problem.

PAY AS LITTLE AS $15

for eligible patients.

Additional Terms and Conditions Apply

Important Safety Information

Important Safety Information

INDICATION

STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

IMPORTANT SAFETY INFORMATION ABOUT STENDRA

  • Administration of STENDRA with any form of organic nitrates, either regularly and/or intermittently, is contraindicated. STENDRA has been shown to potentiate the hypotensive effects of nitrates.
  • STENDRA is contraindicated in patients with a known hypersensitivity to any component of the tablet.
  • Do not use STENDRA in patients who are using a Guanylate Cyclase (GC) stimulator, such as riociguat. PDE 5 inhibitors, including STENDRA may potentiate the hypotensive effects of GC stimulators
  • There is a potential for cardiac risk during sexual activity in patients with preexisting cardiovascular disease. Patients should therefore not use STENDRA if sexual activity is inadvisable due to cardiovascular status or any other reason.
  • Patients with the following characteristics (recent serious cardiovascular events, resting hypotension or uncontrolled hypertension, unstable angina, angina with sexual intercourse, New York Heart Association Class 2 or greater congestive heart failure, or hereditary degenerative retinal disorders, including retinitis pigmentosa) were not included in the clinical safety and efficacy trials. STENDRA is therefore not recommended for those patients.
  • As with other PDE5 inhibitors, STENDRA has systemic vasodilatory properties and may augment the blood pressure-lowering effect of other antihypertensive medications. Physicians should carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity.
  • STENDRA metabolism is principally mediated by the CYP450 isoform 3A4 (CYP3A4). Inhibitors of CYP3A4 may reduce STENDRA clearance and increase plasma concentrations of avanafil. Do not use STENDRA in patients taking concomitant strong CYP3A4 inhibitors. For patients taking concomitant moderate CYP3A4 inhibitors, the maximum recommended dose of STENDRA is 50 mg, not to exceed once every 24 hours.
  • Prolonged erections greater than 4 hours in duration and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. Patients should seek emergency treatment for an erection that lasts longer than 4 hours. If not treated immediately, penile tissue damage and permanent loss of potency could result. Use with caution in patients with anatomical deformation of the penis or in patients with conditions that may predispose them to priapism.
  • Physicians should advise patients to stop use of all PDE5 inhibitors, including STENDRA, and seek medical attention in the event of a sudden loss of vision in one or both eyes. This may be a sign of nonarteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision. STENDRA should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION.
  • Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. Patients experiencing these symptoms should be advised to stop taking STENDRA and seek prompt medical attention.
  • Physicians should discuss with patients the potential for STENDRA to augment the blood pressure-lowering effect of alpha-blockers and other antihypertensive medications.
  • Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. Patients should be stable on alpha-blocker therapy prior to initiating treatment with a PDE5 inhibitor. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose (STENDRA 50 mg). In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dosage may be associated with further lowering of blood pressure when taking a PDE5 inhibitor.
  • Both alcohol and PDE5 inhibitors including STENDRA act as vasodilators. When vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Physicians should therefore inform patients that substantial consumption of alcohol (ie, greater than 3 units) in combination with STENDRA may increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.
  • The safety and efficacy of combinations of STENDRA with other treatments for ED have not been studied. The use of such combinations is therefore not recommended.
  • The safety of STENDRA is unknown in patients with bleeding disorders and patients with active peptic ulceration. In vitro studies with human platelets indicate that STENDRA potentiates the anti-aggregatory effect of sodium nitroprusside (a nitric oxide [NO] donor).
  • The use of STENDRA offers no protection against sexually transmitted diseases. Counseling patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV), should be considered.
  • The most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain.
  • Drug interactions: STENDRA can potentiate the hypotensive effect of nitrates, alpha-blockers, antihypertensives, and alcohol. CYP3A4 inhibitors (eg, ketoconazole, ritonavir, erythromycin) increase STENDRA exposure.

Please see full Prescribing Information.

References: 1. STENDRA [package insert]. Mist Pharmaceuticals.; 2015. 2. Viagra® [package insert]. Pfizer Inc; 2015. 3. Levitra® [package insert]. Bayer Healthcare Pharmaceuticals Inc.; 2015. 4. Staxyn® [package insert]. Bayer Healthcare Pharmaceuticals Inc.; 2015. 5. Cialis® [package insert]. Eli Lilly and Company; 2016. 6. Goldstein I, McCullough AR, Jones LA, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012; 9(4):1122-1133. 7. Goldstein I, Jones LA, Belkoff LH, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc. 2012; 87(9):843-852. 8. Data on File. Clinical Study Report. Mist Pharmaceuticals.; 2014. 9. Mulhall JP, Burnett AL, Wang R, et al. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol. 2013; 189(6):2229-2236. 10. Belkoff LH, McCullough A, Goldstein I, et al. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract. 2013;67(4):333-341.